Amantadine for dyskinesia in patients affected by severe Parkinson's disease

Neurological Sciences

Volumn 22, Issue 1, 2001, Pages 75-76

  Paci, C ^a   Thomas, A ^a   Onofrj, M ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

AGED; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; HYPERTHERMIA; MALE; PARKINSON DISEASE; RATING SCALE;

AGED; AMANTADINE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RECOVERY OF FUNCTION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0034932441     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720170054     Document Type: Conference Paper

References (8)

1. Verhagen M, Del Dotto P, van den Munckhof BS et al (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
2. Stewart A, Factor DO, Molho ES et al (1998) Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 50:1456-1458
3. Uitti RJ, Rajput AH, Ahlskog JE et al (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46:1551-1556
4. Fahn S, Elton R, Members of UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol. 2. Macmillan Health Care Information, Florham Park, pp 153-164
5. Goetz CG, Stebbins GT, Shale HM et al (1994) Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intrarater reliability assessment. Mov Disord 9:390-394
6. Lang AE, Blair RDG (1989) Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB (ed) Drugs for the treatment of Parkinson's disease. Springer, Berlin Heidelberg New York, pp 307-323
7. Snow BJ, Macdonald L, Mcauley D et al (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double blind, placebo-controlled study. Clin Neuropharmacol 23:82-85
8. Porter RHP, Greenamyre JT (1995) Regional variations in the phamacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623